|
|
 |
|
Viewing report
|
|
|
|
Competitor Analysis: Proteasome Inhibitors
La Merie Publishing, Nov 2009, Pages: 14
The present Competitive Intelligence Report about Proteasome Inhibitors provides a competitor evaluation in the field of novel small molecules and peptides targeting the proteasome for treatment of cancer as of November 2009. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
The proteasome is involved in many essential cellular functions, such as regulation of cell cycle, cell differentiation, signal transduction pathways, antigen processing for appropriate immune responses, stress signaling, inflammatory responses, and apoptosis. Due to the importance of the proteasome in cellular functions, inhibition or activation of the proteasome could become a useful therapeutic strategy for a variety of diseases.
Many proteasome inhibitors have been identified and can be classified into two groups according to their source: chemically synthesized small molecules and compounds derived from natural products. A successful example of development of a proteasome inhibitor as a clinically useful drug is the peptide boronate, PS341 (Bortezomib). The drug was approved for the treatment of multiple myeloma. In contrast to proteasome inhibitors, small molecules that can activate or enhance proteasome activity are rare and are not well studied. Despite the commercial success of Velcade, the pipeline of novel proteasome inhibitors is not overcrowded which might indicate the difficulties in identifying new clinical candidates, but also offers a competitive advantage.
The report includes a compilation of current active projects in research and development of molecules targeting the proteasome. In addition, the report lists company-specific R&D pipelines of proteasome targeting small molecules and peptides. Competitor projects are listed in a tabular format providing information on:
- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
Customers who bought this item also bought
Drug Delivery in Cancer - Technologies, Markets and Companies
Oncology Pipeline Database
Commercializing Peptides in Oncology: A Decision Support Tool for Optimizing the Pipeline
Commercializing Peptides in Cancer: The Faster Route to Consider Your Options and Position of Others
Competitor Analysis - Targeted Therapy of Obesity
Cancer Drug Resistance
Competitor Analysis: Novel Mitotic Kinase Inhibitors
Competitor Analysis: Novel Mitotic Kinase Inhibitors
The Targeted Cancer Therapies Pipeline: A Strategic Review
Competitor Analysis: Cytomegalovirus (CMV) Vaccines and Therapeutics
|
|
|
|
